TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03266003

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic DOT
Description: Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded).

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic DOT
Description: Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded).

Intervention type: OTHER
Group type: OTHER
Intervention: In-person DOT
Description: A trained person is in the physical presence of patients as anti-TB drugs are ingested.

Intervention type: OTHER
Group type: OTHER
Intervention: In-person DOT
Description: A trained person is in the physical presence of patients as anti-TB drugs are ingested.
Study: NCT04589689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insul-In This Together
Description: Session 1: Introduction to Parental Monitoring Session 2: Advanced Parental Monitoring Session 3: Introduction to Parental Involvement Session 4: Advanced Parental Involvement Session 5: Introduction to Parent-Teen Conflict Management Session 6: Advanced Parent-Teen Conflict Management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insul-In This Together
Description: Session 1: Introduction to Parental Monitoring Session 2: Advanced Parental Monitoring Session 3: Introduction to Parental Involvement Session 4: Advanced Parental Involvement Session 5: Introduction to Parent-Teen Conflict Management Session 6: Advanced Parent-Teen Conflict Management
Study: NCT03425045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Patients randomised in Arm 1 will receive stimulation of the dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. No medication therapy will be provided for patients in this arm.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation will be performed in patients randomised in Arm 2 of the study for 5 consecutive days. No medication therapy will be provided for patients in this arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba Extract
Description: Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.
Study: NCT01745380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
Study: NCT01677559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Study: NCT01914315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internal Medicine
Description: Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
Study: NCT02056730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium sensing receptor agonist
Description: For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
Study: NCT02847533

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample
Description: blood sample for concentration levels of inflammatory markers

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample
Description: blood sample for concentration levels of inflammatory markers

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychometric scales
Description: Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychometric scales
Description: Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD
Study: NCT03337087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Given PO
Study: NCT02056210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mozobil
Description: Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mozobil
Description: Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
Study: NCT03224767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04147884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Millipede Transcatheter Annuloplasty Ring System (Millipede System)
Description: The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
Study: NCT02412137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseled cohort
Description: This group will be counseled after brace temperature/date/time data is logged at each visit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Counseled cohort
Description: This group will be counseled after brace temperature/date/time data is logged at each visit.
Study: NCT04837625

Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study: NCT01261520

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Culturally-tailored video
Description: A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
Study: NCT03763331

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control/Sham Treatment
Description: Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heat Therapy
Description: Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
Study: NCT03058536

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arabin Pessary
Description: The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone
Description: Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arabin Pessary and Progesterone
Description: Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
Study: NCT01050231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional/ Multi-joints activities
Description: Subjects participated in 4 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder), 3 days per week, 1 hour per day with the robotic exercise program focusing on functional tasks such as cleaning the windows, driving a steering wheel, grocery shopping, etc.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional/ Multi-joints activities
Description: Subjects participated in 4 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder), 3 days per week, 1 hour per day with the robotic exercise program focusing on functional tasks such as cleaning the windows, driving a steering wheel, grocery shopping, etc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individual Joint Training
Description: Subjects participated in 4 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements focusing on one joint at a time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Individual Joint Training
Description: Subjects participated in 4 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements focusing on one joint at a time.
Study: NCT03654534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutrenOpimum
Description: NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
Study: NCT01443546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG
Description: hCG Trigger

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron Trigger
Description: leuprolide acetate 2 mg SQ
Study: NCT04356573

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green Hayward Kiwifruit first, then Gold Kiwifruit
Description: Subjects ate 2 peeled green kiwifruit with their midday meal for 2 weeks prior to testing.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Green Hayward Kiwifruit first, then Gold Kiwifruit
Description: Subjects ate 2 peeled green kiwifruit with their midday meal for 2 weeks prior to testing.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gold Kiwifruit First, then Green Hayward Kiwifruit
Description: Subjects ate 2 peeled gold kiwifruit with their midday meal for 2 weeks prior to testing.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gold Kiwifruit First, then Green Hayward Kiwifruit
Description: Subjects ate 2 peeled gold kiwifruit with their midday meal for 2 weeks prior to testing.
Study: NCT00428194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 40 mg/m\^2 every 7 days during radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 40 mg/m\^2 every 7 days during radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 40 mg/m\^2 every 7 days during radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m\^2 by mouth once a day beginning day 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
Study: NCT02002117

Intervention type: OTHER
Intervention: DNA mass
Description: DNA mass spectrometry
Study: NCT02273206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Care Management for Depression and Cancer Screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevention Care Management for Cancer Screening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Care Management for Cancer Screening
Study: NCT05398575

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Participants listen to music during physiotherapy rehabilitation (tailored or radio music)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants listen to music during physiotherapy rehabilitation (tailored or radio music)
Study: NCT01764854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 (in-patient)
Description: doses between 5 and 60 mg BID may be administered based on tolerability in a CPU setting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (in-patient)
Description: Placebo, size and color matched to experimental drug administered in a CPU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1722 (out-patient)
Description: doses between 5 and 45 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, size and color matched to experimental drug
Study: NCT05299229

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogrpahy and non-invasive monitoring
Description: Study participants will have echocardiography and non-invasive monitoring by chest/back sensors and a finger cuff.
Study: NCT03430700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT03866681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: The dose of sirolimus is adjusted according to monitored serum concentration, maintain Rapamycin concentration ranging from 4 to 10ng/ml.Warfarin was administered orally at a dose of 1mg per day for a year,then gradually reduced to stop.
Study: NCT04698044

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety Depression Scale
Description: HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety Depression Scale
Description: HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety Depression Scale
Description: HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).
Study: NCT00117273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]
Description: 1 tablet daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonique (LNG/EE and EE)
Description: 1 tablet daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Portia (LNG/EE)
Description: 1 tablet daily x 28 days
Study: NCT02806908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01443546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual Trigger
Description: a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
Study: NCT00946088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone 400 mg per vagina qhs.
Study: NCT00403481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Olmesartan medoxomil tablets, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil plus Hydrochlorothiazide
Description: Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
Study: NCT00127231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention based on Project Treat
Description: The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Hazardous/binge female drinkers will be identified in the Johns Hopkins Hospital HIV clinic and will be randomized to brief intervention or standard care. Outcome measures will include: alcohol/drug use, engagement in an on-site alcohol support group and other substance abuse treatment services, HIV-risk behaviors, HIV disease markers and treatment compliance, and psychiatric symptoms.